ARVINAS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.55 USD | +2.72% |
|
-7.83% | -40.39% |
| Jul. 01 | Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell 3000E Value Index | CI |
| Jul. 01 | Arvinas, Inc.(NasdaqGS:ARVN) dropped from Russell 2000 Value Index | CI |
Chart calendar Arvinas, Inc.
7402c51a37.6SkYawfEKOHDctKfGV5XSn95JNx5b3EILip52ixojNY.i19fJFGDUdWpFrD1KSYkG00NCYY0HR4xQVgek044vZGtbH0aT_FmhJAUuQ~c842b41bbbe53b7a1dcad94790763bf4
Upcoming events on Arvinas, Inc.
Past events on Arvinas, Inc.
| 2024-06-10 10:40 am | Goldman Sachs Global Healthcare Conference |
| 2024-06-06 11:00 am | Jefferies Global Healthcare Conference |
| 2024-06-03 02:15 pm | American Society of Clinical Oncology Meeting - Abstract No 5011 |
| 2024-06-02 10:00 am | American Society of Clinical Oncology Meeting - Abstract No TPS1131 |
| 2024-05-29 08:30 am | Annual General Meeting |
| 2024-05-20 | UBS Spring Biotech Conference |
| 2024-05-16 06:00 am | European Society for Medical Oncology Breast Cancer Congress - Abstract, 453 |
| 2024-05-14 06:00 pm | BofA Securities Health Care Conference |
| 2024-05-07 07:00 am | Q1 2024 Earnings Release |
| 2024-04-16 03:00 pm | Stifel Virtual Targeted Oncology Days Conference |
| 2024-03-18 09:00 am | UBS Virtual CNS Day |
| 2024-03-12 | Jefferies Biotech on the Bay Summit |
| 2024-03-12 01:00 pm | Leerink Partners Global Biopharma Conference |
| 2024-02-27 07:00 am | Q4 2023 Earnings Release |
| 2024-02-07 10:30 am | Guggenheim Healthcare Talks Biotechnology Conference - Fireside Chat |
| 2023-12-08 01:00 pm | San Antonio Breast Cancer Symposium - Poster No:PO5-14-11 |
| 2023-12-07 06:30 pm | San Antonio Breast Cancer Symposium |
| 2023-12-07 01:00 pm | San Antonio Breast Cancer Symposium - Poster No:PO3-05-08 |
| 2023-12-06 06:00 pm | San Antonio Breast Cancer Symposium - Poster No:PO2-20-04 |
| 2023-12-06 06:00 pm | San Antonio Breast Cancer Symposium - Poster No:PO2-20-03 |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 43,0 40,3 6.55% | 21,8 26,2 -16.76% | 46,7 36,5 27.87% | 131 121 8.77% | 78,5 170 -53.85% | 177 |
|
EBITDA Million USD | Released Forecast Spread | -50,0 -49,7 -0.55% | -122 -114 -6.63% | -191 -15,4 -1137.11% | -257 -252 -1.99% | -397 -284 -39.66% | -374 |
|
EBIT Million USD | Released Forecast Spread | -51,5 -49,5 -4.17% | -125 -114 -9.7% | -195 -143 -37% | -263 -259 -1.72% | -402 -307 -30.97% | -323 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -70,3 -61,9 -13.59% | -119 -97,0 -23.05% | -191 -180 -6.11% | -262 -250 -4.5% | -364 -277 -31.49% | -265 |
|
Net income Million USD | Released Forecast Spread | -70,3 -65,4 -7.46% | -119 -108 -10.4% | -191 -179 -6.97% | -283 -258 -9.59% | -367 -275 -33.43% | -256 |
|
EPS USD | Released Forecast Spread | -2,13 -2,11 -1.08% | -3,02 -2,72 -10.85% | -3,82 -2,73 -39.86% | -5,31 -4,91 -8.22% | -6,62 -5,07 -30.6% | -3,96 |
| Announcement Date | 16/03/20 | 01/03/21 | 28/02/22 | 23/02/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 24,2 25,5 -5.14% | 31,3 23,7 32.03% | 30,3 34,7 -12.73% | 38,0 35,3 7.58% | 32,5 27,7 17.18% | 54,5 31,0 75.91% | 34,6 40,1 -13.62% | -43,1 49,3 -187.43% | 25,3 32,1 -21.08% | 70,5 | 43,3 | 44,7 | 37,8 | 40,1 |
|
EBITDA Million USD | Released Forecast Spread | -164 -9,84 -1567.14% | -82,1 -93,6 12.28% | -78,3 | -93,5 | -98,4 | |||||||||
|
EBIT Million USD | Released Forecast Spread | -60,0 -51,0 -17.61% | -68,3 -58,2 -17.31% | -67,2 -65,2 -3.11% | -75,4 -67,0 -12.5% | -87,7 -83,3 -5.31% | -74,6 -91,1 18.13% | -73,9 -88,3 16.34% | -165 -73,4 -125.08% | -83,3 -97,7 14.7% | -55,2 | -80,7 | -95,2 | -99,7 | -104 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -58,9 -48,2 -22.24% | -66,6 -54,0 -23.23% | -64,0 -58,1 -10.17% | -72,1 -58,7 -22.93% | -81,2 -80,7 -0.57% | -65,6 -88,0 25.43% | -63,9 -81,2 21.29% | -153 -67,3 -127.8% | -69,3 -88,8 21.99% | -36,7 | -69,1 | -91,0 | -99,0 | -104 |
|
Net income Million USD | Released Forecast Spread | -63,4 -47,7 -32.96% | -70,0 -57,7 -21.36% | -66,2 -57,1 -15.92% | -82,9 -57,9 -43.18% | -81,9 -81,6 -0.41% | -66,6 -88,7 24.91% | -64,0 -83,1 22.98% | -155 -64,9 -138.53% | -69,4 -90,7 23.5% | -33,3 | -70,8 | -82,8 | -82,2 | -87,8 |
|
EPS USD | Released Forecast Spread | -1,20 -0,92 -30.62% | -1,32 -1,06 -24.1% | -1,24 -1,12 -10.57% | -1,56 -1,17 -33.08% | -1,54 -1,55 0.84% | -1,25 -1,65 24.41% | -1,18 -1,57 24.69% | -2,53 -1,15 -119.25% | -0,97 -1,34 27.86% | -0,58 | -1,04 | -1,17 | -1,16 | -1,17 |
| Announcement Date | 05/05/22 | 04/08/22 | 08/11/22 | 23/02/23 | 05/05/23 | 08/08/23 | 07/11/23 | 27/02/24 | 07/05/24 | - | - | - | - | - |
More events
Past sector events for Arvinas, Inc.
| 2024-06-05 03:51 am | PHARMAESSENTIA CORPORATION: May 2024 Sales and Revenue Release |
| 2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
| 2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 2024-05-15 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
| 2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:05 pm | ENLIVEN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 04:00 pm | ARCUTIS BIOTHERAPEUTICS, INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ARVN Stock
- Calendar Arvinas, Inc.
